Preparing the structured Flagship evidence library.
Flagship peptide evidence profile
These are deterministic research-intelligence signals, not clinical conclusions.
This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.
global evidence atlas
This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Cureus · 2023 Sep · PMID 37854744 · DOI 10.7759/cureus.45421
Type 2 diabetes and glycemia · Cardiovascular outcomes · Safety and tolerability
Diabetes, obesity & metabolism · 2023 Mar · PMID 36314246 · DOI 10.1111/dom.14908
Type 2 diabetes and glycemia · Safety and tolerability
Pediatric obesity · 2021 Oct · PMID 33963681 · DOI 10.1111/ijpo.12799
Weight loss and obesity · Pediatric and adolescent research · Mechanism and pharmacology
BMC endocrine disorders · 2022 Apr 7 · PMID 35392872 · DOI 10.1186/s12902-022-01006-6
Type 2 diabetes and glycemia
Diabetes, obesity & metabolism · 2026 Aug 13 · PMID 42595732 · DOI 10.1111/dom.71204
Type 2 diabetes and glycemia · Mechanism and pharmacology
Obesity research & clinical practice · 2025 Jan-Feb · PMID 39904668 · DOI 10.1016/j.orcp.2025.01.009
Weight loss and obesity
Clinics and research in hepatology and gastroenterology · 2021 May · PMID 33309563 · DOI 10.1016/j.clinre.2020.10.012
MASH and liver
Healthcare (Basel, Switzerland) · 2021 Aug 30 · PMID 34574899 · DOI 10.3390/healthcare9091125
Comparative effectiveness
Clinical and experimental hypertension (New York, N.Y. : 1993) · 2020 Jul 3 · PMID 31610701 · DOI 10.1080/10641963.2019.1676771
Type 2 diabetes and glycemia · Cardiovascular outcomes
African health sciences · 2019 Sep · PMID 32127832 · DOI 10.4314/ahs.v19i3.35
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability
Diabetes research and clinical practice · 2024 Jan · PMID 38061446 · DOI 10.1016/j.diabres.2023.111034
Type 2 diabetes and glycemia · Safety and tolerability · Ongoing development
Diabetes, obesity & metabolism · 2016 Jul · PMID 26936426 · DOI 10.1111/dom.12653
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Endocrine · 2015 Apr · PMID 25115635 · DOI 10.1007/s12020-014-0373-0
Type 2 diabetes and glycemia · Mechanism and pharmacology · Comparative effectiveness
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025 Feb · PMID 39401933 · DOI 10.1016/j.soard.2024.08.037
Weight loss and obesity
Obesity surgery · 2025 Mar · PMID 39885064 · DOI 10.1007/s11695-025-07671-5
Weight loss and obesity
International journal of psychiatry in clinical practice · 2025 Nov · PMID 40849800 · DOI 10.1080/13651501.2025.2549307
Weight loss and obesity
Clinical epidemiology · 2022 · PMID 36510488 · DOI 10.2147/CLEP.S391819
Weight loss and obesity · Safety and tolerability
BMC endocrine disorders · 2019 Jan 7 · PMID 30616638 · DOI 10.1186/s12902-018-0332-5
Cardiovascular outcomes
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017 Feb · PMID 27995594 · DOI 10.1007/s13300-016-0217-4
Type 2 diabetes and glycemia · Comparative effectiveness
Diabetes, obesity & metabolism · 2016 Jul · PMID 26662611 · DOI 10.1111/dom.12617
Weight loss and obesity · Type 2 diabetes and glycemia
Diabetes, obesity & metabolism · 2016 Jul · PMID 26679282 · DOI 10.1111/dom.12623
Weight loss and obesity · Type 2 diabetes and glycemia
Diabetes care · 2015 Jun · PMID 25504028 · DOI 10.2337/dc13-1210
Type 2 diabetes and glycemia · Safety and tolerability
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2011 May-Jun · PMID 21700561 · DOI 10.4158/EP10215.RA
Kidney outcomes · Safety and tolerability
Sleep & breathing = Schlaf & Atmung · 2023 Oct · PMID 36542275 · DOI 10.1007/s11325-022-02768-y
Type 2 diabetes and glycemia · Safety and tolerability
The Journal of clinical endocrinology and metabolism · 2022 Aug 18 · PMID 35833597 · DOI 10.1210/clinem/dgac369
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Liraglutide · PMID 39258838
At week 56, the mean percentage change from baseline in BMI was -5.8% with liraglutide and 1.6% with placebo, representing an estimated difference of -7.4 percentage points (95% confidence interval [CI], -11.6 to -3.2; P<0.001).
Liraglutide · PMID 35015037
Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338).
Liraglutide · PMID 27295427
The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio.
Liraglutide · PMID 26132939
At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).